



1 19 July 2018
2 EMA/CVMP/AWP/706442/2013
3 Committee for Medicinal Products for Veterinary Use (CVMP)

4 **Guideline on the assessment of the risk to public health**
5 **from antimicrobial resistance due to the use of an**
6 **antimicrobial veterinary medicinal product in food-**
7 **producing animals**
8 **Draft 2**

| | |
|--|------------------|
| Draft agreed by Antimicrobials Working Party (AWP) | 21 January 2015 |
| Adopted by CVMP for release for public consultation | 12 February 2015 |
| Start of the first public consultation | 24 February 2015 |
| End of the first public consultation (deadline for comments) | 31 August 2015 |
| Updated draft guideline agreed by Antimicrobials Working Party | 12 June 2018 |
| Adopted by CVMP for release for public consultation | 19 July 2018 |
| Start of the second public consultation | 27 July 2018 |
| End of the second public consultation (deadline for comments) | 31 October 2018 |

9
10

Comments should be provided using this [template](#). The completed comments form should be sent to vet-guidelines@ema.europa.eu

11

| | |
|----------|--|
| Keywords | antimicrobial resistance (AMR), risk assessment, antimicrobial veterinary medicinal products |
|----------|--|

12



13 Guideline on the assessment of the risk to public health
14 from antimicrobial resistance due to the use of an
15 antimicrobial veterinary medicinal product in food-
16 producing animals

17 **Table of contents**

18 **Executive summary 3**

19 **1. Introduction (background)..... 3**

20 **2. Scope..... 3**

21 **3. Legal basis 4**

22 **4. When does this guidance apply?..... 4**

23 **5. Methodology for the risk assessment 5**

24 **6. Data sources and quality 9**

25 **7. Data requirements..... 9**

26 7.1. Hazard identification9

27 7.2. Release assessment..... 12

28 7.3. Exposure assessment 16

29 7.4. Consequence assessment..... 17

30 **8. Overall qualitative risk estimation..... 20**

31 **Definitions for the purpose of this guideline..... 21**

32 **References 23**

33

34 **Executive summary**

35 This guideline provides advice in regards to applications for Marketing Authorisations for antimicrobial
36 veterinary medicinal products (VMPs) on the data required and the methodology to be used for
37 performing an assessment of the risk to public health from antimicrobial resistance (AMR) due to use
38 of the product. The scope of the guidance extends to VMPs intended for food producing species and to
39 the transmission of AMR by the foodborne route or through direct contact with treated animals.

40 The risk assessment methodology is adapted from that described by the World Organisation for Animal
41 Health (OIE). Other relevant methodology such as that of Codex Alimentarius was also taken into
42 account for the preparation of this guidance (see chapter 5). The steps required take into account: the
43 identification of resistant bacteria or resistance determinants that could be associated with human
44 illness and are selected by the use of the antimicrobial VMP in animals; the probability of exposure of
45 zoonotic and commensal bacteria in the target animal species based on the conditions of use of the
46 VMP under consideration; the probability of subsequent human exposure to AMR, and the resulting
47 consequences to human health. Guidance is given on data quality and possible data sources for each
48 step of the risk assessment process. It is recognised that there will be data gaps and therefore it is
49 recommended that a qualitative approach is taken to give a final estimation of the overall risk to public
50 health due to AMR.

51 **1. Introduction (background)**

52 The CVMP Strategy on Antimicrobials advises that CVMP will consider available data on antimicrobial
53 resistance (AMR) and give AMR-related risks adequate weight in the benefit-risk assessment when
54 deciding to authorise, or restrict use of, an antimicrobial veterinary medicinal product. In regards to
55 the risk to public health, food has always been regarded as an important route through which human
56 beings may be exposed to antimicrobial-resistant bacteria, and there is now increasing concern in
57 regards to the risk of exposure through direct contact with livestock for certain organisms. Although
58 the VICH GL 27¹ already provides guidance on data requirements for registration of new veterinary
59 medicinal products for food producing animals with respect to AMR, not all aspects of the risk
60 assessment are addressed and there are no recommendations on how the final risk estimation should
61 be concluded. Increasing concern has been raised from many parties in regards to the impact on public
62 health of the use of antimicrobials in animals. Therefore, this guidance on the risk assessment part of
63 the risk analysis process for antimicrobial veterinary medicinal products is aimed to provide a
64 systematic approach to the evaluation of the associated scientific data and to improve the
65 transparency and consistency of the regulatory decision-making process.

66 **2. Scope**

67 The purpose of this guideline is to provide guidance on the data required and the methodology to be
68 applied to the assessment of the risk to public health from AMR in relation to Marketing Authorisation
69 applications and referrals for antimicrobial veterinary medicinal products for use in food producing
70 species.

71 The risk question to be addressed is:

72 *What is the risk to human health from antimicrobial-resistant bacteria resulting from the intended use*
73 *of the proposed veterinary medicinal product?*

¹ VICH GL 27: Guidance on pre-approval information for registration of new veterinary medicinal products for food producing animals with respect to antimicrobial resistance. <http://www.vichsec.org/en/topics.htm#8>

74 In regards to the risk to human health, this includes a consideration of the consequences of AMR
75 including loss of treatment options, increased disease severity and/or mortality and the increased
76 burden on healthcare services. This should be considered in the context of the community and hospital
77 populations within the EU, with attention to specific vulnerable sub-populations or geographical regions
78 as needed.

79 The risk assessment should address both the current state of play and, for a new Marketing
80 Authorisation application, the potential change in the risk based on the proposed conditions of use
81 going forwards. It is acknowledged that certain elements of the risk assessment, including emergence
82 of novel resistance mechanisms and change in the importance of the antimicrobial to human health,
83 will be speculative and associated with uncertainty.

84 The scope of this guidance extends to antimicrobial veterinary medicinal products (VMPs) intended to
85 treat food producing species, and that potentially select resistant bacteria or resistance determinants
86 that may be transmitted through foodstuff of animal origin or by direct contact with the target species
87 and subsequently have an impact on human health.

88 Direct contact relates to exposure through handling animals or animal products and may therefore be
89 relevant for those such as farm workers, animal owners, veterinarians, abattoir workers, those
90 handling food of animal origin and people (including children) who may visit farms.

91 Although there are many other potential routes of human exposure to antimicrobial-resistant bacteria
92 (e.g. via general environmental contamination) it is currently difficult to attribute the resistance to use
93 of VMPs and these routes are not within scope of this guidance. CVMP is developing a separate
94 reflection paper on AMR in the environment. VMPs for companion animals, including horses not
95 intended for human consumption, are also excluded from the scope of this guidance. The
96 EMA/CVMP/AWP has published a reflection paper on the risk of antimicrobial resistance transfer from
97 companion animals (EMA/CVMP/AWP/401740/2013)².

98 The steps of risk management and risk communication that are essential for a complete risk analysis
99 are not discussed in this guideline. It is, however, acknowledged that the risk assessment process may
100 help to identify appropriate risk management steps and the data provided for the risk assessment
101 should be tailored to the veterinary medicinal product in question and the specific conditions of its use
102 where relevant. "Off label" use, including misuse, does not have to be considered within the risk
103 assessment.

104 **3. Legal basis**

105 This guideline should be read in conjunction with the introduction and general principles and
106 requirements for safety tests laid out in Annex I to the Directive 2001/82 as amended, which requires
107 data to be provided on the potential for emergence of antimicrobial-resistant bacteria of relevance for
108 human health.

109 **4. When does this guidance apply?**

110 The specified data and risk assessment should be provided in support of:

- 111 • Any Marketing Authorisation application for an antimicrobial substance not previously authorised
112 for use in a veterinary medicinal product for food producing species in the EU.

² http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500181642.pdf

- 113 • Any application for a combination of antimicrobial substances not previously authorised for use in a
114 veterinary medicinal product for use in food producing species in the EU.
 - 115 • Any application relating to an antimicrobial substance previously authorised for use in a food
116 producing species that could lead to an increase in volume of use or an increased risk to public
117 health, e.g.
 - 118 — A change to the dosage form or pattern of use or exposure e.g. a change from
119 individual animal use to group medication; a change in the formulation from injectable
120 to in-feed/in-water medication.
 - 121 — Extension to a new major food-producing species.
 - 122 — Addition of another major group within the same food-producing species (e.g. beef
123 cattle to dairy cattle).
 - 124 — Addition of new major therapeutic indications.
 - 125 — Any change to the dosing regimen.
 - 126 • Referral procedures that include concerns over the AMR risk to human health.
- 127 A separate risk assessment should be provided for each formulation/ animal species/ indication/ dosing
128 regimen, although parts of the assessment are common to more than one scenario.
- 129 The guidance does not apply for generic applications made under Article 13.1 of the Directive.
- 130 For other cases, such as Marketing Authorisation applications for minor species or minor indications, a
131 risk assessment should be provided unless a justification can be given that this will not present a new
132 hazard or significantly increase the exposure to AMR.

133 5. Methodology for the risk assessment

134 The risk assessment methodology has been adapted from that that described by the OIE (Antimicrobial
135 resistance: risk analysis methodology for the potential impact on public health of antimicrobial
136 resistant bacteria of animal origin; Vose et al, 2001³; OIE Terrestrial Animal Health Code, chapter
137 6.10). In addition, note has been taken of the methodology proposed by Codex (Guidelines for risk
138 analysis of foodborne antimicrobial resistance, CAC/GL 77-2011⁴) and the requirements in place in
139 other jurisdictions (FDA⁵, Health Canada⁶, APVMA⁷). The OIE methodology is used as the basis for this
140 CVMP guidance to facilitate alignment with models used in other regulatory jurisdictions and due to the
141 particular applicability of the “release assessment” step to the risk analysis for VMPs. The methodology
142 takes into account: knowledge of the mechanisms of resistance to the antimicrobial under

³ Antimicrobial resistance: risk analysis methodology for the potential impact on public health of antimicrobial resistant bacteria of animal origin. Vose D, Acar J, Anthony F, Franklin A, Gupta R, Nicholls T, Tamura Y, Thompson S, Threlfall EJ, van Vuuren M, White G, Wegener HC, Costarrica ML. Rev.sci.tech.Off.int.Epiz., 2001, 20(3),811-827.

⁴ <http://www.codexalimentarius.org/search-results/?cx=018170620143701104933%3Ai-zresgmxec&cof=FORID%3A11&q=antimicrobial&siteurl=http%3A%2F%2Fwww.codexalimentarius.org%2F&sa.x=19&sa.y=9>

⁵ US Department of Health and Human Services, Food and Drug Administration, Center for Veterinary Medicine, October 23, 2003. Guidance for Industry #152. Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to their Microbiological Effects on Bacteria of Human Health Concern.

<http://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/ucm123614.htm>

⁶ Health Canada, Veterinary Drugs Directorate Guidance for Industry – 2005. Guidance document for microbiological safety studies requirements for preparation of veterinary new drug submissions. Health Canada: http://www.hc-sc.gc.ca/dhp-mps/vet/antimicrob/amr-ram_rep-rap_06_05-eng.php

⁷ Australian Pesticides and Veterinary Medicines Authority. Veterinary Manual of Requirements and Guidelines, Part 10 – Special Data: Antibiotic Resistance. <https://apvma.gov.au/node/1018>

143 consideration; the probability of exposure of zoonotic and commensal bacteria in the target species
144 based on the conditions of use of the veterinary medicinal product under consideration; the probability
145 of subsequent human exposure to AMR via food or direct animal contact and also, as the assessment
146 relates to the risk to human health, the importance of the antimicrobial substance to human medicine
147 and consequences to human health. As the risk assessment is for a specific antimicrobial VMP, more
148 emphasis is placed on the impact of the conditions of use relevant to the product, and less emphasis
149 on aspects that relate to risk factors that are not product-related e.g. impact of methods of food
150 processing on bacterial load in foods.

151 The following steps in the risk assessment structure should be followed:

- 152 • **Hazard identification:** the identification of antimicrobial-resistant bacteria or resistance
153 determinants therein that could be associated with human illness and are selected due to the use
154 of the concerned antimicrobial substance in the target animal species. Resistance may develop
155 both in bacteria that are zoonotic and/or in commensal bacteria in animals that could pass
156 resistance determinants to other bacteria that are pathogenic in humans.
- 157 • **Release Assessment:** the biological pathways necessary for use of the specific antimicrobial
158 veterinary medicinal product in the target species and to bring about selection of resistant bacteria
159 in the animal up to the time of "release" at slaughter, collection of food produce or through direct
160 contact with a handler, and an estimation of the probability of that complete process happening.
- 161 • **Exposure Assessment:** the biological pathways necessary for exposure (via food or direct
162 contact) of humans to the identified hazard(s) (resistant bacteria/determinants) following from the
163 point of release from the target species to the point of food consumption or direct contact, and an
164 estimation of the amount of exposure and probability of its occurring.
- 165 • The division of the risk assessment into "release" and "exposure" components effectively separates
166 animal and animal treatment factors that are associated with use of the specific VMP (release) from
167 food-chain and human factors (exposure).
- 168 • **Consequence Assessment:** The potential consequences (adverse health effects) of exposure of
169 humans to the hazard and the severity and probability of the consequences occurring. The
170 consequence assessment for resistant bacteria may be informed by that for non-resistant
171 organisms; however, it relates to consequences over and above those caused by an antimicrobial-
172 sensitive strain of a pathogen, and unless the resistance also results in increased transmission or
173 virulence, only to circumstances where antimicrobial treatment would be required. [In accordance
174 with Codex, this step is also known as "Hazard Characterisation"].
- 175 • **Risk estimation:** The integration of the key findings from the release, exposure and consequence
176 assessments to produce an overall measure of the risk associated with the hazard identified at the
177 outset. The risk estimation therefore takes into account the entire risk pathway from the hazard(s)
178 identified to the unwanted outcome.

179 **Categorisation of risk factors / Assessment scales**

180 It is recognised that there are likely to be substantial data gaps that preclude a quantitative approach
181 to this risk assessment. Consequently, this guidance proposes that a qualitative approach is taken,
182 although, where quantitative data are available applicants are encouraged to refine the approach. A
183 structured and transparent approach should still be taken to the assessment. It is recommended that
184 the key risk factors are assessed as very low (VL), low (L), medium (M) or high (H) relative to the
185 range of possible outcomes. Examples are given in the release, exposure and consequence assessment
186 sections of this guidance. These may be refined by the applicant according to the specific conditions of

187 use of the product, e.g. species production sub-type, countries where the MA is sought if not a
188 centrally authorised product. An overall categorisation (VL, L, M, H) should be given at the end of each
189 section of the assessment, although it is recognised that the weighting of each contributing risk factor
190 is somewhat arbitrary.

191 The following categorisation may be used for the release and exposure assessment:

- 192 • Very low – very low probability that release/exposure to the hazard can occur (plausible, but
193 very unlikely).
- 194 • Low – Low probability for release/exposure to occur.
- 195 • Medium – Medium probability for release/exposure to occur (likely, probable).
- 196 • High – Significant probability for release/exposure to occur (very likely, certain).

197 A separate categorisation for the consequence assessment is included at the end of section 7.4.

198 **Uncertainty and variability**

199 The applicant should comment on any assumptions that have been made, especially in relation to data
200 gaps or poor understanding of risk pathways. Uncertainty (due to lack of, or poor quality, data) may be
201 described as low, medium or high. For example:

202 Low uncertainty – abundant high quality data leading to consistent conclusions.

203 Medium uncertainty – limited amount of data.

204 High uncertainty – no data available leading to reliance on expert opinion.


205 In regards to variability in data (e.g. variation between EU countries in prevalence of resistance), if this
206 is significant an option may be to present scenarios considering best, most common and worst case for
207 the risk factor.

208 The uncertainty and variability associated with each factor/parameter and the influence these may
209 have on the reliability and generalisability of the overall risk assessment should be evaluated. Within
210 this context, the risk assessor should still aim to provide a clear summary of the available data and
211 conclusion at the end of each step of the assessment.

212 An example of the risk assessment approach is given in the publication by Alban et al. (2017);
213 although in this case the context was that of use of an established antimicrobial.

214 The risk assessment should take into account the proposed conditions and anticipated extent of use of
215 the veterinary medicinal product (e.g. target species, indication, route of administration, treatment
216 incidence, see below 7.2) and is therefore specific to those circumstances. By integrating the release,
217 exposure and consequence assessments, the potential risk of the identified hazard(s) should be
218 estimated. An acceptable level of risk is that which when weighed against the proposed benefits of use
219 of the veterinary medicinal product in the target species, will not significantly compromise therapeutic
220 use of antibiotics in humans or human health. Risk management measures to minimise the risk to
221 public health from use of the VMP may also be taken into account. The acceptability of the risk level
222 has to be weighed in the context of the overall benefit-risk as determined from the complete dossier
223 for the product. This aspect is not addressed further here as this guidance document only addresses
224 the risk assessment process. Further guidance on the evaluation of the benefit-risk for VMPs is given in
225 the document: Recommendation on the evaluation of the benefit-risk balance of veterinary medicinal
226 products (EMA/CVMP/248499/2007).

227 **Figure 1:** Possible pathways and components of antimicrobial risk assessment for a veterinary
 228 medicinal product for use in food producing species.



229
 230

231 6. Data sources and quality

232 Possible sources of information include, for example, data presented in other sections of the dossier
233 (e.g. pharmacodynamics, residues), information from national and EU databases (EMA, EFSA, ECDC),
234 investigations of outbreaks or sporadic cases of infections associated with AMR organisms, and
235 scientific studies investigating the potential for antimicrobial substances to select for antimicrobial-
236 resistant organisms and the transfer of genetic determinants. Acceptable data will include sponsor-
237 generated studies, official reports and peer-reviewed literature references. Sponsor generated studies
238 should (ideally) be conducted in compliance with GLP and/or GCP, as applicable. For MIC studies, data
239 for key organisms should be consistent with the requirements in VICH GL 27 and where originating
240 from surveillance programmes, these should be relevant to the EU for the last 5 years. For new
241 antimicrobial substances that have not previously been used within the EU, then information from third
242 countries may be of value if available. In addition, if substance-specific data are not available, then
243 reference may be made to related molecules within the same antimicrobial class, in which case a
244 justification of the relevance of the reference should be provided.

245 When data are not available in public literature or from the sponsor's own studies, then expert opinion
246 may be used. In this case, it is better for the applicant to solicit the views of more than one expert.
247 Where there are complete data gaps, these should be highlighted as areas of high uncertainty.

248 7. Data requirements

249 7.1. Hazard identification

250 This step addresses the identification of antimicrobial-resistant bacteria or resistance determinants that
251 could result in human illness and may be selected due to the use of the antimicrobial substance
252 concerned in the target animal species. Resistance may develop both in bacteria that are zoonotic
253 and/or in commensal bacteria in animals that could pass transferable resistance determinants to other
254 bacteria that are pathogenic in humans. In regards to zoonotic pathogens, attention should be focused
255 on those for which the concerned antimicrobial/class is a recognised treatment in human medicine in
256 the EU. For the purpose of this risk assessment, only bacteria that are foodborne or may be transferred
257 by direct contact with animals need to be considered. A non-exhaustive list is given in Annex 1.

258 **Table 1:** Hazard identification, data requirements and guidance.

| Data required | Detail | Further guidance on resources |
|--|---|--|
| Substance-specific information. | Antimicrobial class. | See VICH GL 27, section 1.1 |
| | Mechanism of action. | See VICH GL 27, section 1.2 |
| | Spectrum of activity. | See VICH GL 27, section 1.3 |
| Taking into account the target animal species to be treated, the applicant should identify and justify the bacterial species for which resistance to the antimicrobial of concern has potential human health consequences. | This includes: <ul style="list-style-type: none">• Foodborne pathogens (e.g. <i>Campylobacter</i>, <i>Salmonella</i>);• Bacteria that could be transmitted by direct contact (e.g. <i>Staphylococcus</i> | See VICH GL27, section 1.3. In addition consider bacteria that may be transmitted by direct contact. |

| Data required | Detail | Further guidance on resources |
|---|--|--|
| | <p><i>aureus</i>);</p> <ul style="list-style-type: none"> Indicator/commensal bacteria that may carry mobile resistance determinants that could be passed to human pathogenic bacteria (e.g. <i>Escherichia coli</i>, <i>Enterococcus</i> spp). | |
| Resistance mechanisms associated with the antimicrobial in animal and human bacteria. | E.g. antimicrobial inactivation, alteration of target, efflux pumps. | See VICH GL 27, section 1.4 |
| Genetic basis of resistance – | | Cross-reference can be made, as appropriate to the information supplied in accordance with the revised CVMP Guideline for the demonstration of efficacy for veterinary medicinal products containing antimicrobial substances. |
| <ul style="list-style-type: none"> Intrinsic | Presence of any intrinsic resistance genes which may be expressed under certain circumstances either constitutively or inducibly. | |
| <ul style="list-style-type: none"> Acquired – chromosomal (mutational) or acquisition of resistance determinants | Whether resistance is related to chromosomal mutation or acquisition of mobile genetic elements (such as plasmids) carrying the resistance determinant, or may be related to both. | |
| Location of resistance determinants | e.g. chromosomal, plasmid, transposons including information on whether resistance is transferred vertically and/or horizontally. Association of resistance determinants with mobile genetic elements. | |
| Occurrence of cross-resistance and co-resistance. | This relates to antimicrobials approved for use in both human and/or veterinary medicine whose efficacy could be compromised. Both a phenotypic and genotypic description should be provided. | See VICH GL 27, sections 1.6 and 1.7 Cross-reference can be made, as appropriate to the information supplied in accordance with the CVMP Guideline for the demonstration of efficacy for veterinary medicinal products containing antimicrobial |


| Data required | Detail | Further guidance on resources |
|---|--|--|
| | | substances (currently under revision). |
| Susceptibility data (MIC distribution /MBC) for the bacteria of human health concern. | MIC values should be determined with validated methods, where possible. Clinical breakpoints and epidemiological cut-off values (ECOFFs) should be considered in the assessment. | See VICH GL 27, section 1.3 |

259 The applicant should provide a discussion that leads to an overall conclusion on the opportunity for
260 selection of antimicrobial-resistant bacteria /determinants that could result in resistant infections in
261 humans, and may be selected due to the use of the concerned antimicrobial substance in the target
262 animal species. This discussion should focus on the interaction of the antimicrobial with the individual
263 identified pathogens and commensals together with their associated resistance mechanism/ genes, and
264 considering:

- 265 • intrinsic or acquired resistance
- 266 • location of resistance determinants and whether resistance is transferred vertically and/or
267 horizontally
- 268 • the possibility of co- and cross-selection of resistance to other antimicrobials
- 269 • the presence of resistance determinants in the EU; consideration of determinants known to exist in
270 third countries or in other microbiomes such as in waste water

271

272 For each hazard identified, the release, exposure and consequence assessments are then mapped
 273 forwards individually, for example:
 274



275
 276

277 **7.2. Release assessment**

278 This step addresses the biological pathways necessary for use of the specific antimicrobial veterinary
 279 medicinal product in the target species and to bring about selection of resistant bacteria in the animal
 280 up to the time of "release" at slaughter, harvest of food produce from the animal or direct contact with
 281 a handler, and an estimation of the probability of that complete process happening.

282 **Table 2:** Release assessment, data requirements and guidance.

| Data required | Detail | Further guidance on resources and interpretation of data |
|---|--|--|
| Product description Conditions of use, estimate of usage | Formulation Target species and production type (e.g. beef cattle); husbandry practices; disease indication and its prevalence; estimate of the number and age (body weight) of animals likely to be exposed in a given time frame; potential for dissemination of AMR between animals and premises. | Eurostat ⁸ , ESVAC ⁹ data on PCU for the target species ¹⁰ e.g. High – pigs, cattle, poultry Medium – small ruminants Low – fish, horses Very low - rabbits The categorisation above may be used as a starting point and may be refined according to the specific conditions. Higher risk would be associated e.g. with common diseases requiring regular treatment, major species; husbandry requiring high level of human contact with the target group. Lower risk would be associated with minor species, rare diseases. |
| Resistance selection pressure | Envisaged extent of use of the product: dose regimen and justification for duration of use; route of administration (individual/mass, local/systemic, parenteral/oral) Selection pressure from AMs that may induce co-/cross-resistance. | ESVAC sales data for substance (and species/production category, if available). Higher risk would be associated with herd/flock treatments, especially those administered orally via food or drinking water. Lower risk would be associated with individual animal treatments, and with products which are administered locally so that gastrointestinal-tract exposure is limited. Longer duration of treatment effect could be associated with higher risk of AMR selection. |

⁸ Eurostat is the statistical office of the European Union.
<http://epp.eurostat.ec.europa.eu/portal/page/portal/eurostat/home/>

⁹ The European Surveillance of Antimicrobial Consumption.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000302.jsp

¹⁰ PCU: Population Correction Unit, as used by ESVAC. See http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000302.jsp For the purpose of this guideline, high is > 10,000 PCU, medium >5,000 – 10, 000, low > 1,000 – 5,000, very low < 1,000.

| Data required | Detail | Further guidance on resources and interpretation of data |
|--|---|--|
| PK and PD of the antimicrobial | <p>ADME¹¹ in the target animal species.</p> <p>PD: impact on zoonotic and commensal flora. Concentration-, time- or co-dependent effects, PAE¹², Minimal Selective Concentration and sub-MIC¹³ effects etc.</p> <p>PK/PD¹⁴ in respect of bacterial species identified as potential hazards to human health, if available.</p> | Some of this information may be obtained from Part 4 of the dossier, in accordance with the CVMP Guideline for the demonstration of efficacy for veterinary medicinal products containing antimicrobial substances (currently under revision). See VICH GL 27, section 1. |
| Occurrence and rate of transfer of resistance determinants | <p>Studies may be included to demonstrate both <i>in vitro</i> or <i>in vivo</i> rate and extent of resistance selection. This may include studies conducted in laboratory animals or the target species, and <i>in vitro</i> mutation frequency studies.</p> <p>Can resistance determinants be transferred horizontally between bacteria and to bacteria of different species (transformation, transduction, conjugation) and at what rate? Do findings from <i>in vitro</i> conditions reflect field situation?</p> | <p>See VICH GL 27, sections 1.5 and 2.1</p> <p>See information in response to Q.2 of the Commission's request for scientific advice on the impact on public and animal health of the use of antibiotics in animals (EMA/381884/2014, Table 3)¹⁵.</p> |
| Estimation of the concentration of the antimicrobial agent in the intestinal lumen of the target animal under proposed conditions of use and expected effects on colon microbiota. | Antimicrobial activity may be due to parent antimicrobial or metabolites. An indication should be given of the expected effects on resistance selection in the intestinal microbiota and on the possible duration of shedding of resistant organisms. | <p>See VICH GL 27, section 2.2.</p> <p>It may be possible to extrapolate from data contained in Part 3 of the dossier (microbiological properties of residues), where specific data for the target species are not available.</p> <p>Higher risk would be associated with antimicrobial concentrations ranging within the selective window for relevant organisms of the microbiome.</p> |

¹¹ ADME: absorption, distribution, metabolism, excretion.

¹² PAE: post antibiotic effect

¹³ MIC: minimal inhibitory concentration

¹⁴ PK/PD: pharmacokinetics/pharmacodynamics

¹⁵ http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/07/WC500170253.pdf

| Data required | Detail | Further guidance on resources and interpretation of data |
|---|---|--|
| Prevalence of carriage of zoonotic bacteria and commensals in target animal population and baseline prevalence of resistance in those bacteria. | <p>Epidemiological data on the existing prevalence of resistance to the antimicrobial in question and related antimicrobials in zoonotic bacteria and commensals identified as potential hazards in the target animal.</p> <p>In relation to direct contact, literature studies may be available on meat and skin carriage of relevant bacteria in the target species and prevalence in the immediate farm environment.</p> | <p>E.g. The European Union Summary Report on Trends and Sources of Zoonoses, Zoonotic Agents and Food-borne Outbreaks (EFSA/ECDC).¹⁶</p> <p>In consistency with EFSA, the following ranking may be used for the proportion of positive sample units or prevalence of zoonotic agents:</p> <p>high >20%, medium >10% to 20%, low >1% to 10%, v. low ≤1%</p> <p>The European Union Summary Report on Antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in the European Union (EFSA/ECDC)¹⁷ Other sources may also be used, e.g. CEESA.¹⁸</p> <p>In consistency with EFSA, the percentage of resistant isolates as a proportion of those tested may be expressed as: high > 20%, medium > 10% to 20%, low > 1% to 10% or v. low ≤ 1%</p> |
| Other relevant information | Studies to investigate rate of resistance selection in foodborne bacteria following use of the product under proposed conditions of use and rate of decline after cessation of therapy, in relation to time of slaughter/harvest. | Influence of withdrawal period or period between treatment and slaughter could be considered in the assessment. |

283 The applicant should assess whether the evidence relating to each factor points towards high, medium,
284 low or very low (H, M, L, VL) probability of favouring resistance emergence in relative terms for each
285 identified hazard. An indication of the categorisation for some factors is given in the table above
286 ('interpretation of data').

287 The applicant should provide a discussion that leads to the overall conclusion on the probability (H, M,
288 L, VL) that antimicrobial-resistant bacteria/determinants will be selected for and "released" as a result

¹⁶ <http://www.efsa.europa.eu/en/topics/topic/monitoringandanalysisoffood-borne-diseases.htm?wtrl=01>

¹⁷ <http://www.efsa.europa.eu/en/topics/topic/amr.htm>

¹⁸ The European Animal Health Study Centre (CEESA): European Antimicrobial Susceptibility Surveillance in Animals Programme (EASSA).

289 of the proposed use of the product in animals, together with an indication of the uncertainty (H, M, L)
 290 and variability (see section 5).

291 **7.3. Exposure assessment**

292 This step addresses biological pathways necessary for exposure (via food or direct contact) of humans
 293 to the hazard(s) (resistant bacteria/determinants) following from the point of release from the target
 294 species to the point of food consumption or direct contact, and an estimation of the amount of
 295 exposure and probability of its occurring.

296 The division of the risk assessment into “release” and “exposure” components effectively separates
 297 animal and animal treatment factors that are associated with use of the specific VMP (release) from
 298 food-chain and human factors (exposure). It is acknowledged that certain factors such as the way that
 299 food of animal origin is processed, transported, stored and cooked have a strong influence on microbial
 300 load in specific food products at the point of consumption. These factors are assumed to be
 301 independent of the conditions of use of a specific antimicrobial VMP. In order to simplify the approach,
 302 the factors a) to d) below may be used as the minimum data set to summarise the final estimate of
 303 foodborne exposure. Where point of consumption data are unavailable, data from an earlier stage of
 304 the risk pathway (e.g. at point of sale) might be provided as an alternative if justified.

305 **Table 3:** Exposure assessment, data requirements and guidance.

| Data required | Detail | Further guidance on resources |
|--|---|--|
| a) Human consumption patterns for food produce from target species in the EU | This refers to major produce classes associated with the target animal, e.g. meat (beef, pork, chicken, turkey, etc); dairy produce; fish; eggs | EFSA EU Comprehensive Food Consumption Database ¹⁹ /Eurostat, FAO-OECD ²⁰ High (> 20 kg per capita p.a.) – pork, poultry, fish meat Medium (>10-20 kg per capita p.a.) – beef/veal Low (> 1-10 kg per capita p.a.) – sheep meat V low (< 1 kg per capita p.a.) |
| b) Prevalence of food contamination at point of consumption with bacteria relevant to the hazard (excluding produce imported from outside EU). | | EFSA/ECDC Zoonosis reports. Data may also be provided on extent of secondary contamination due to food processing, handling etc. which would be excluded for the purpose of this risk assessment |
| c) Microbial load of food at point of consumption | | |

¹⁹ <http://www.efsa.europa.eu/en/datexfoodcdb/datexfooddb.htm>

²⁰ <https://data.oecd.org/agroutput/meat-consumption.htm>

| Data required | Detail | Further guidance on resources |
|---|--|--|
| d) Prevalence of resistance to antimicrobial in those bacteria | | The European Union Summary Report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food |
| e) Data from source attribution studies | Please refer to Scientific Opinion of the Panel on Biological Hazards on a request from EFSA ON Overview of methods for source attribution for human illness from foodborne microbiological hazards. <i>The EFSA Journal</i> (2008) 764,1-43 ²¹ | |
| f) Data to characterise probability of human exposure through direct contact, e.g. number of people exposed to the animal during rearing, carcass at slaughter and processing, farm visits; human prevalence surveys. | | A distinction between professional contact (occupational hazard reports) and occasional contact (e.g. children on farm visits) might be indicated. Studies may be available demonstrating levels of human carriage or colonisation with resistant bacteria. |

306 The applicant should provide a discussion that leads to the overall conclusion on the amount of
307 exposure of humans to antimicrobial-resistant organisms/determinants via food at the point of
308 consumption or through direct contact, and the probability of its occurring. The categorisation of the
309 exposure (H, M, L, VL) can be used, together with an indication of the uncertainty (H, M, L) and
310 variability (see section 5).

311 **7.4. Consequence assessment**

312 This step addresses the potential consequences (adverse health effects on the individual and burden
313 on healthcare services) of exposure of humans to each of the hazard(s) in the EU and the severity and
314 probability of the consequences occurring.

315 The consequence assessment for resistant bacteria may be informed by that for non-resistant
316 organisms; however, it relates to consequences over and above those caused by a sensitive strain of a
317 pathogen, and unless the resistance also results in increased virulence, only to circumstances where
318 antimicrobial treatment would be required.

319 It is acknowledged that there may be a high level of uncertainty in the estimate of the proportion of
320 infections due to resistant organisms in humans that can be attributed to animal sources, especially
321 where the resistance originates from commensals.

²¹ <http://www.efsa.europa.eu/en/efsajournal/pub/764.htm>

322 Consideration should be given to community and hospital populations, with attention to specific
 323 vulnerable sub-populations or geographical regions as needed.

324 **Table 4:** Consequence assessment, data requirements and guidance.

| Data required | Detail | Further guidance on resources |
|---|--|---|
| a) Relative importance of the antimicrobial to human medicine | <p>Spectrum of activity and important disease indications (including target pathogens) for use in humans.</p> <p>Availability of alternative antimicrobial treatments.</p> <p>Extent of use in human medicine.</p> | <p>See published background information to the AMEG's categorisation of antimicrobials - scientific advice to be finalised in 2019.</p> <hr/> <p>ESAC database²²</p> |
| b) Dose-response relationships (where available) | <p>A description of the relationship between the frequency and magnitude of exposure of humans to the resistant organisms and the severity and frequency of the impact; including an estimate of the critical threshold of exposure required to cause infection in susceptible humans.</p> | |
| c) Consequences of AMR in human infections | <p>Number of cases of human infection reported (and estimate of unreported cases) per annum.</p> <p>Number/proportion of cases attributed to animal food produce/animal contact.</p> <p>Severity of disease: deaths, long term impacts, number of days illness, hospitalisation (length of stay, additional treatment).</p> <p>Prevalence of antimicrobial resistance in human isolates and attribution to animal source (where possible).</p> | <p>The European Union Summary Report on Trends and Sources of Zoonoses, Zoonotic Agents and Food-borne Outbreaks.</p> <p>European Surveillance System (TESSy)²³ – ECDC.</p> <p>Scientific Opinions from EFSA Panel on biological hazards (BIOHAZ).</p> |

²² European Surveillance of Antimicrobial Consumption.

http://www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/esac-net-database/Pages/database.aspx

²³ The European Surveillance System database.

<http://www.ecdc.europa.eu/en/activities/surveillance/tessy/Pages/TESSy.aspx>

| Data required | Detail | Further guidance on resources |
|---------------|--|-------------------------------|
| | <p>Any increase in transmission or severity and duration of illness due to increased virulence of AMR of pathogens compared to sensitive organisms.</p> <p>Extent of need for antimicrobial treatment (cost), due to interference with first line treatments, treatment failures, availability of alternative treatments, loss of treatment options.</p> <p>Susceptibility of vulnerable human sub-populations.</p> <p>Horizontal transmission of resistance determinants.</p> | |

325 The applicant should provide a discussion that leads to the overall conclusion on the potential adverse
326 health effects of exposure of humans to the hazard(s) and the severity and probability of those
327 consequences occurring.

328 The following categorisation may be used:

329 Very low – The antimicrobial is of very low importance in terms of the frequency of use to treat a
330 disease for which alternatives are commonly available and the outcomes due to resistant organisms
331 are not different.

332 Low - The antimicrobial is of low to medium importance in terms of the frequency of use to treat a
333 disease for which the outcomes are more serious with impact on the individual and on healthcare
334 services.

335 Medium - The antimicrobial is of medium to high importance in terms of the frequency of use to treat a
336 disease for which the outcomes are more serious with impact on the individual and on healthcare
337 services, requiring (possibly prolonged) hospitalisation.

338 High - The antimicrobial is a last resort treatment (or one of few alternatives) for a disease for which
339 the outcome of treatment failure is very severe requiring lengthy hospitalisation or resulting in
340 disability or death.

341 Alternatively, as a **pragmatic approach**, the consequence assessment can be based on a combination
342 of (i) the AMEG categorisation for the substance/class and (ii) the extent of use of the class in human
343 medicine in the EU. For hospital use this should be reported preferably as DDD per 1000 patient days
344 or DDD per 1000 admissions, and for community use it should be reported as DDD per 1000
345 inhabitants per day, if these data are available. Annex 2 gives an indicative categorisation based on
346 European consumption data for 2016, obtained courtesy of ESAC-Net.

347 The ranking for the consequence element is then derived according to the matrix below:

| AMEG category | Extent of use in human medicine | | | |
|---------------|---------------------------------|--------|--------|--------|
| | Very low | LOW | MEDIUM | HIGH |
| 3 | High | High | High | High |
| 2 | High | High | High | High |
| 2/1 | Low | Medium | Medium | High |
| 1 | Very low | Low | Low | Medium |

348

349 This table will be subject to revision and finalised after the [AMEG scientific advice](#) is completed.

350

351 8. Overall qualitative risk estimation

352 The risk estimation integrates the results from the release, exposure and consequence assessments to
 353 produce an overall estimate of the risk to public health from antimicrobial-resistant bacteria resulting
 354 from the use of the proposed veterinary medicinal product in accordance with its SPC. The risk
 355 estimation therefore takes into account the entire risk pathway from each of the hazards identified to
 356 the unwanted outcomes. It should be presented as a summary of the key influencing data from each
 357 step of the process and a final risk conclusion. Any assumptions and uncertainty that might impact the
 358 final risk estimate, or degree of confidence that can be held in it, should be commented upon.
 359 Variability under different scenarios (e.g. livestock production systems, geographical regions) should
 360 also be briefly addressed where relevant.

361

362

363

364 **Definitions for the purpose of this guideline**

365 **Adverse health effect** - An unwanted outcome in humans. Specifically here, this is a human illness
366 due to AMR organisms in food, or acquired through direct animal contact, as well as increased
367 frequency of infections, treatment failures, loss of treatment options and increased severity of disease
368 manifested by prolonged duration of disease, increased hospitalisation, disability and mortality.

369 **Antimicrobial** - A naturally occurring, semi-synthetic or synthetic substance that exhibits
370 antimicrobial activity (kills or inhibits the growth of micro-organisms) at concentrations attainable *in*
371 *vivo*. Antiparasitics and substances classed as disinfectants or antiseptics are excluded from this
372 definition (OIE Terrestrial Animal Health Code definition). In the context of this guideline, the focus is
373 on compounds acting against bacteria.

374 **Antimicrobial resistance** – Antimicrobial resistance is the ability of microorganisms of a certain
375 species to survive or even grow in the presence of a given concentration of an antimicrobial agent that
376 is usually sufficient to inhibit or kill microorganisms of the same species (Directive 2003/99/EC²⁴).

377 **Clinical breakpoint** – For definition please refer to EUCAST:
378 <http://www.srga.org/Eucastwt/eucastdefinitions.htm>

379 **Co-resistance** –The presence of resistance to more than one class of antimicrobial in the same
380 bacterial strain, as might occur when different resistance genes are found on the same plasmid.

381 **Co-selection of resistance** –The selection of multiple AMR genes when one of these is selected by
382 the presence of a relevant antimicrobial. An example of this is the integron, which may carry a gene
383 cassette(s) encoding AMR genes that is (are) under the control of a single promoter. As a result, these
384 genes are expressed in a coordinated manner, although the furthest downstream gene may not be as
385 efficiently expressed as the gene next to the promoter. These cassettes are commonly found in both
386 Gram-positive and Gram-negative bacteria. They can become a part of the bacterial chromosome or
387 plasmid and can then be transmitted amongst different bacterial strains.

388 **Cross-resistance** – A single resistance mechanism confers resistance to an almost entire class of
389 antimicrobials. An example is the aminoglycoside-modifying enzymes which may confer resistance to
390 several members of the aminoglycoside family. Cross resistance can occur across different classes of
391 agents - a result of either overlapping drug targets, as is the case with macrolides and lincosamides, or
392 a drug efflux pump with a broad range of activity (i.e. capable of exporting different classes of drugs).

393 **Foodborne commensals** – [VICH GL 27] non-zoonotic bacterial species living in the intestinal content
394 of animals that could be transmitted to humans by the food chain and that normally do not cause
395 foodborne infections in humans.

396 **Foodborne pathogens** – [VICH GL 27] zoonotic organisms of which animals could be carriers in the
397 intestinal content, that could be transmitted to humans by the food chain and subsequently cause
398 food-borne infections in humans.

399 **Hazard** – A hazard is something that is potentially harmful. With respect to antimicrobial resistance,
400 the hazards are antimicrobial-resistant bacteria or their transferable genetic determinants.

²⁴ Official Journal of the European Union. Directive 2003/99/EC of the European Parliament and of the Council of 17 November 2003 on the monitoring of zoonoses and zoonotic agents, amending Council Decision 90/424/EEC and repealing Council Directive 92/117/EEC. In <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:325:0031:0040:EN:PDF>.

401 **Risk** – The probability of an adverse effect and the severity of that effect, consequential to exposure to
402 a hazard.

403 **Risk assessment** – The process of evaluating the risk(s) resulting from a hazard. A risk assessment
404 usually describes the risk in terms of the probability of an unwanted outcome.

405 **Uncertainty** – This reflects a lack of knowledge that can be reduced by additional data or information.

406 **Variability** –The heterogeneity of the subjects modelled, including both randomness and inter-
407 individual variability. Variability cannot be reduced by additional data or information.

408 **Zoonotic bacteria** [WHO, 2004] - Bacteria that are present in animal reservoirs and can be
409 transferred to, and cause infections in, humans.

410

411 **References**

- 412 Alban L, Ellis-Iversen J, Andreasen M, Dahl J and Sönksen UW. 2017. Assessment of the Risk to Public
413 Health due to the use of Antimicrobials in Pigs – an example of Pleuromutilins in Denmark Front. Vet.
414 Sci. 4:74.
- 415 Australian Pesticides and Veterinary Medicines Authority. Veterinary Manual of Requirements and
416 Guidelines, Part 10 – Special Data: Antibiotic Resistance.
417 http://www.apvma.gov.au/morag_vet/vol_3/part_10_special.php
- 418 CVMP Strategy on Antimicrobials 2011-2015.
419 http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/07/WC500109137.pdf
- 420 EFSA (European Food Safety Authority), 2008. Scientific Opinion of the Panel on Biological Hazards on
421 foodborne antimicrobial resistance as a biological hazard. EFSA Journal. 765, 1-87.
- 422 EMA/CVMP/AWP reflection paper on the risk of antimicrobial resistance transfer from companion
423 animals (EMA/CVMP/AWP/401740/2013).
424 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC50018164
425 [2.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC50018164_2.pdf)
- 426 Health Canada, Veterinary Drugs Directorate Guidance for Industry – 2005. Guidance document for
427 microbiological safety studies requirements for preparation of veterinary new drug submissions. Health
428 Canada: http://www.hc-sc.gc.ca/dhp-mps/vet/antimicrob/amr-ram_rep-rap_06_05-eng.php
- 429 Kersh, Gilbert J. "Antimicrobial therapies for Q fever." Expert review of anti-infective therapy 11.11
430 (2013): 1207-1214.
- 431 Official Journal of the European Union. Directive 2003/99/EC of the European Parliament and of the
432 Council of 17 November 2003 on the monitoring of zoonoses and zoonotic agents, amending Council
433 Decision 90/424/EEC and repealing Council Directive 92/117/EEC. In [http://eur-](http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:325:0031:0040:EN:PDF)
434 [lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:325:0031:0040:EN:PDF](http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:325:0031:0040:EN:PDF).
- 435 US Department of Health and Human Services, Food and Drug Administration, Center for Veterinary
436 Medicine, October 23, 2003. Guidance for Industry #152. Evaluating the Safety of Antimicrobial New
437 Animal Drugs with Regard to their Microbiological Effects on Bacteria of Human Health Concern.
438 <http://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/ucm1236>
439 [14.htm](http://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/ucm123614.htm)
- 440 VICH GL 27: Guidance on pre-approval information for registration of new veterinary medicinal
441 products for food producing animals with respect to antimicrobial resistance.
442 <http://www.vichsec.org/en/topics.htm#8>
- 443 Vose D, Acar J, Anthony F, Franklin A, Gupta R, Nicholls T, Tamura Y, Thompson S, Threlfall EJ, van
444 Vuuren M, White G, Wegener HC, Costarrica ML. Antimicrobial resistance: risk analysis methodology
445 for the potential impact on public health of antimicrobial resistant bacteria of animal origin.
446 [http://www.codexalimentarius.org/search-results/?cx=018170620143701104933%3Ai-](http://www.codexalimentarius.org/search-results/?cx=018170620143701104933%3Ai-zresgmxec&cof=FORID%3A11&q=antimicrobial&siteurl=http%3A%2F%2Fwww.codexalimentarius.org%2F&sa.x=19&sa.y=9)
447 [zresgmxec&cof=FORID%3A11&q=antimicrobial&siteurl=http%3A%2F%2Fwww.codexalimentarius.org](http://www.codexalimentarius.org/search-results/?cx=018170620143701104933%3Ai-zresgmxec&cof=FORID%3A11&q=antimicrobial&siteurl=http%3A%2F%2Fwww.codexalimentarius.org%2F&sa.x=19&sa.y=9)
448 [%2F&sa.x=19&sa.y=9](http://www.codexalimentarius.org/search-results/?cx=018170620143701104933%3Ai-zresgmxec&cof=FORID%3A11&q=antimicrobial&siteurl=http%3A%2F%2Fwww.codexalimentarius.org%2F&sa.x=19&sa.y=9)
- 449 WHO/FAO. Risk Characterisation of Microbiological Hazards in Food: Guidelines, 2009..
450
451

452 **Annex 1**

453 **Zoonotic and commensal bacteria present in different food-producing species in which**
 454 **carriage of AMR could be a hazard to human health (non-exhaustive):**

| Bacterial species | Routes of exposure | Animal species that are possible sources |
|---|--|---|
| Zoonotic bacteria | | |
| <i>Campylobacter</i> spp e.g. <i>jejuni</i> , <i>coli</i> | Food (meat, milk) (Contact) | Poultry (<i>jejuni</i>) Pigs (<i>coli</i> , <i>jejuni</i>) Cattle Sheep, goats Fish |
| <i>Salmonella</i> spp | Food (meat, eggs, milk) Contact | Pigs (Typhimurium) Poultry (<i>Infantis</i> , <i>Enteritidis</i>) Cattle (<i>Typhimurium</i> , <i>Dublin</i>) Sheep, goats Horses Fish |
| <i>Leptospira hardjo</i> | Contact | Cattle |
| <i>Coxiella burnetii</i> ¹ | Contact, local environment. (Food - milk) | Cattle Sheep, goats |
| <i>Staphylococcus aureus</i> including MRSA | Contact (Food - milk) | Pigs Poultry Cattle Horses |
| <i>Brucella</i> spp | Contact Food (milk) | Cattle (<i>abortus</i>) Sheep, goats (<i>melitensis</i>) (Pigs) (<i>suis</i>) |
| <i>Bacillus anthracis</i> | Contact | Cattle, sheep, goats, pigs, horses |
| <i>Chlamydia psittaci</i> | Contact | Sheep Poultry |
| <i>Pasteurella multocida</i> | Contact | Pigs, cattle, poultry |

455

456

| | | |
|--|-----------------|---|
| <i>Streptococcus suis</i> Other zoonotic streptococci (e.g. <i>S. equi subsp. zooepidemicus</i>) | Contact | Pigs Other species. |
| <i>Vibrio parahaemolyticus</i> , <i>V. vulnificus</i> <i>Mycobacterium marinum</i> <i>Aeromonas hydrophila</i> | Food Contact | Fish Vibrio are not included for other spp as they are primarily food contaminants from aqueous / marine environments. |
| Commensals (indicator organisms) | | |
| <i>E coli</i> | Food Contact | All |
| <i>Enterococcus faecalis</i> , <i>faecium</i> | Food Contact | All |
| <i>Aeromonas hydrophila</i> | Food, contact | Fish |

457 ¹*Coxiella burnetii* is an obligate intracellular pathogen. Results of *in vitro* susceptibility testing
 458 (requiring specialised methods) have been described in the scientific literature. It is accepted that the
 459 available literature is not extensive (Kersh, G.J. 2013).

460

461

462 **Annex 2**

463

464 **Consumption of antibacterials for systemic use (DDD per 1000 inhabitants per day),**
 465 **ambulatory care sector (AC, data from 29 countries) and hospital sector (HC, data from 23**
 466 **countries) combined, EU/EEA, 2016.** Based on data provided courtesy of ESAC-Net.
 467

| Antibacterial class | ATC code | Consumption (DDD per 1000 inhabitants per day) | Categorisation (as provided by CVMP)* |
|---|----------------|---|--|
| Tetracyclines, incl. glycylcyclines | J01AA | 60.30 | M |
| Amphenicols | J01BA | 0.08 | VL |
| Penicillins with extended spectrum | J01CA | 121.22 | H |
| Beta-lactamase sensitive penicillins | J01CE | 24.68 | M |
| Beta-lactamase resistant penicillins | J01CF | 12.57 | L |
| Combinations of penicillins, incl. beta-lactamase inhibitors | J01CR | 153.38 | H |
| 1 st - and 2 nd -generation cephalosporins | J01DB, J01DC | 55.27 | M |
| 3 rd - and 4 th -generation cephalosporins | J01DD, J01DE | 13.55 | L |
| Monobactams | J01DF | 0.04 | VL |
| Carbapenems | J01DH | 1.83 | L |
| Sulfonamides and trimethoprim, incl. combinations | J01EA to J01EE | 17.58 | L |
| Macrolides | J01FA | 74.99 | M |
| Lincosamides | J01FF | 8.79 | L |
| Streptogramins | J01FG | 0.89 | VL |
| Aminoglycoside antibacterials | J01GA, J01GB | 2.58 | L |
| Quinolone antibacterials | J01MA, J01MB | 55.92 | M |
| Glycopeptide antibacterials | J01XA | 1.03 | L |
| Polymyxins | J01XB | 0.72 | VL |
| Steroid antibacterials | J01XC | 0.25 | VL |
| Imidazole derivatives | J01XD | 2.03 | L |
| Nitrofurans derivatives | J01XE | 18.17 | L |

468 *VL (very low), <1.0; L (low), 1.0 to <20.0; M (medium), 20.0 to 100, H (high), >100 DDD per 1000
 469 inhabitants per day.
 470